Mar. 6 at 1:03 PM
$PMN From Promis' website:
About The Trial
PMN310 in Patients with Early Alzheimer's Disease (PRECISE-AD)
This study is a Phase 1b, randomized, double-blind, placebo-controlled, multi-ascending dose study of repeat doses of PMN310 to evaluate the safety, tolerability, PK, PD, and preliminary efficacy of multiple intravenous infusions of PMN310 in patients with early Alzheimer's disease. This study will evaluate 3 dose levels (5 mg/kg, 10mg/kg, and 20 mg/kg are planned). Patients will be randomly assigned 3:1, PMN310: placebo.
Each patient will receive PMN310 or placebo once every 28 days for a total of 12 infusions.
My point: Promis starting testing patients 14 months ago. In one of the 'Fireside chats', CEO Mr. Neil Warma eludes to the fact that the efficacy is effective at 5 mg/kg and that the 20 mg/kg, (which is on-going), is more drug than is necessary.
* Without any doubt, the BOD's, CEO, management, etc., already know PMN310 works, with improved efficacy and no ARIA!!!
